Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Neurocrine Biosciences Inc (NBIX) vs Riot Platforms Inc (RIOT) Price & Performance

Neurocrine Biosciences IncTrade
Riot Platforms IncTrade

Price performance (Past 24H)

Key statistics

Neurocrine Biosciences Inc vs Riot Platforms Inc — how do they compare? Neurocrine Biosciences Inc trades at $156 (market cap $16.46B), while Riot Platforms Inc trades at $20.31 (market cap $7.59B). The key difference: Neurocrine Biosciences Inc is far larger — about 2.2× Riot Platforms Inc's market cap. Which is the better fit depends on your goals.

NBIXRIOT
Market Cap
$16.46B$7.59B
Sector
HealthTechnology
52-Week High
$185.50$28.67
52-Week Low
$123.10$11.33
Enterprise Value
$16.48B$8.00B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Neurocrine Biosciences Inc

Neurocrine Biosciences (NBIX) trades at $156.95, down 4.83% in the last session, with a bearish technical signal from moving averages and ADX. The stock shows strong fundamentals, including a 39% year-over-year revenue growth in Q2 2026 to $959 million and a net income margin of 20.91% for 2026. Recent developments include positive INGREZZA clinical data and the initiation of a Phase 1 study for a GLP-1/GIP/glucagon receptor triple agonist, though safety concerns were raised for Vykat XR in Prader-Willi Syndrome.

The outlook for NBIX is positive with a consensus price target of $208.82, implying 33% upside, supported by robust earnings beats and portfolio expansion. Risks include drug safety issues, competitive pressures, and reliance on INGREZZA sales. Investors should weigh strong analyst bullishness against regulatory and execution risks in the biopharmaceutical sector.

Riot Platforms Inc

RIOT Platforms trades at $20.835, up 7.4% on news of a transformative $9.1 billion AI infrastructure deal with Anthropic. Despite bearish technical signals and consecutive quarterly losses, the stock shows strong momentum driven by the company's strategic pivot from bitcoin mining to data center operations. Analyst sentiment remains overwhelmingly positive with 94% buy ratings and a $33.40 consensus price target, representing significant upside potential.

The outlook hinges on successful execution of the AI infrastructure strategy, though substantial risks persist including negative cash flow, widening losses, and competitive pressures. Investors face a high-risk, high-reward scenario where the massive Anthropic deal could drive long-term value if operational challenges are overcome.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Read more on NBIX

About Riot Platforms Inc

Riot Platforms, Inc. is a Bitcoin mining company that focuses on building, operating, and expanding large-scale infrastructure for digital asset mining in North America. The company's operations include Bitcoin mining, data center hosting, and engineering solutions. Riot's strategy emphasizes vertical integration to maximize efficiency and scale its mining capacity, aiming to be a leader in the global Bitcoin and digital infrastructure industry.

Read more on RIOT